Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Why targeted therapies are necessary for systemic lupus erythematosus
L. Durcan,
M. Petri
School of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
12
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Why targeted therapies are necessary for systemic lupus erythematosus'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Systemic Lupus Erythematosus
100%
belimumab
58%
Population Characteristics
41%
Precision Medicine
38%
Prednisone
36%
Interferon-alpha
35%
Cell- and Tissue-Based Therapy
33%
Immunosuppressive Agents
29%
B-Lymphocytes
27%
Clinical Trials
23%
Morbidity
20%
Mortality
17%
Therapeutics
17%